Acadia Pharmaceuticals (ACAD) risk factors, FY2024 10-K

Risks Related to Our Products and Product Candidates

1. 01Our prospects are highly dependent on the successful commercialization of our products. To the extent we cannot maintain or increase sales of our products, our business, financial condition and results of operations may be materially adversely affected and the price of our common stock may decline
2. 02any negative publicity related to our products
3. 03Our products may not gain maximal acceptance among physicians, patients, caregivers and the medical community, thereby limiting our potential to generate revenues
4. 04our ability to obtain and maintain sufficient third-party insurance coverage or adequate reimbursement levels
5. 05If we do not obtain regulatory approval of trofinetide outside North America, we will not be able to market trofinetide outside North America, which will limit our commercial revenues
6. 06Our ability to generate product revenues will be diminished if coverage for our products from commercial or government payors is decreased or if patients have unacceptably high out-of-pocket requirements
7. 07Our products are subject to ongoing regulatory requirements that could cause us significant expense and delay or limit our ability to generate sales revenues
8. 08seizure or detention, or refusal to permit the import or export of products
9. 09We rely on a limited network of third-party distributors and pharmacies to market and sell our products. If this approach ceases to be effective, commercialization of our products may be adversely affected, and our products may not be profitable
10. 10Drug development is a long, expensive and unpredictable process with a high risk of failure, and there is no guarantee that our products or product candidates will be successful in ongoing or future clinical trials or obtain regulatory approval
11. 11the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities
12. 12With the completion of the Pediatric Phase 2 Trial, we believe we now have completed the FDA’s requirements to qualify for a pediatric exclusivity for pimavanserin. However, there is no assurance that FDA will confirm that such requirements have been met and that the pediatric exclusivity will be granted
13. 13Expanded access or compassionate use programs could subject us to additional risks
14. 14Delays, suspensions and terminations in our clinical trials for our product candidates could result in increased costs to us and delay our ability to generate product revenues
15. 15obtaining institutional review board approval to conduct a clinical trial at a prospective clinical trial site; and
16. 16insufficient supply or deficient quality of product candidates or other materials necessary for the conduct of our clinical trials

Risks Related to Our Business

1. 17If we fail to develop, acquire or in-license other product candidates or products, our business and prospects would be limited. Even if we obtain rights to other product candidates or products, we will incur a variety of costs and may never realize the anticipated benefits
2. 18We have a history of net losses and we may not be able to predict the extent of future losses
3. 19We may require additional financing in the future to fund our operations. If we cannot raise additional financing in the future, we may be unable to fund our business plan and our future research, development, commercial and manufacturing efforts
4. 20the costs associated with litigation, including the costs incurred in defending against any product liability claims that may be brought against us related to our products
5. 21We expect that our results of operations will fluctuate, which may make it difficult to predict our future performance from period to period
6. 22We believe that comparisons from period to period of our financial results are not necessarily meaningful and should not be relied upon as indications of our future performance
7. 23Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations
8. 24Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited
9. 25Tax authorities could reallocate our taxable income among our subsidiaries, which could increase our overall tax liability
10. 26Unfavorable global economic conditions could adversely affect our business, financial condition or results of operations
11. 27We or the third parties upon whom we depend may be adversely affected by catastrophic events, such as earthquakes, fires or other natural disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster
12. 28We have incurred, and expect to continue to incur, significant costs as a result of laws and regulations relating to corporate governance and other matters
13. 29Our business involves the use of hazardous materials, and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business
14. 30Our management has broad discretion over the use of our cash and we may not use our cash effectively, which could adversely affect our results of operations

Risks Related to Our Relationships with Third Parties

1. 31We depend on collaborations with third parties to develop certain of our product candidates and may need to enter into future collaborations to develop and commercialize certain of our product candidates
2. 32cannot obtain the necessary regulatory approvals
3. 33Our collaborations may be subject to conflicts or disputes, which could have a material adverse effect on our business, results of operations and financial condition
4. 34Conflicts arising with our collaborators could impair the progress of our product candidates, harm our reputation, result in a loss of revenues, reduce our cash position, and cause a decline in our stock price
5. 35the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners
6. 36We rely on third parties to conduct our clinical trials and perform data collection and analysis, which may result in costs and delays that prevent us from successfully commercializing product candidates, if approved
7. 37the quality or accuracy of the data obtained by these third parties is compromised due to their failure to adhere to our clinical protocols or regulatory requirements or for other reasons
8. 38We have no manufacturing facilities and only limited experience as an organization in the manufacturing of drugs or in designing drug-manufacturing processes. We have contracted with third-party manufacturers to produce, in collaboration with us, our products and product candidates
9. 39pre-market approval of drugs, delays, suspension or withdrawal of approvals, seizures or recalls of products, operating restrictions, and criminal prosecutions
10. 40We may not be able to continue or fully exploit our collaborations with outside scientific and clinical advisors, which could impair the progress of our clinical trials and our research and development efforts

Risks Related to Our Intellectual Property

1. 41Our ability to compete may decline if we do not adequately protect our proprietary rights
2. 42technology that we may in-license may become important to some aspects of our business; however, we generally would not control the patent prosecution, maintenance or enforcement of any such in-licensed technology
3. 43Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete
4. 44A dispute concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time-consuming and costly, and an unfavorable outcome could harm our business
5. 45As a result, we could be prevented from commercializing current or future products
6. 46The patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position

Risks Related to Government Regulation and Our Industry

1. 47Healthcare reform measures may negatively impact our ability to sell NUPLAZID, DAYBUE or our product candidates, if approved, profitably
2. 48In both the U.S. and certain foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to sell our products, as described in greater detail in the Government Regulation section of this report
3. 49The implementation of cost-containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products
4. 50The Swiss Federal Act on Data Protection, or the FADP, also applies to the collection and processing of personal data, including health-related information, by companies located in Switzerland, or in certain circumstances, by companies located outside of Switzerland
5. 51We could face liability if a regulatory authority determines that we are promoting our products for any “off-label” uses
6. 52Changes at the FDA and other government agencies could delay or prevent new products from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal functions on which the operation of our business may rely, which could negatively impact our business
7. 53We are subject to stringent regulation in connection with the marketing of our products, which could delay the development and commercialization of our products
8. 54If our competitors develop and market products that are more effective than our products, they may reduce or eliminate our commercial opportunity
9. 55commercializing pharmaceutical products
10. 56If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products, or development or commercialization of our product candidates, if approved
11. 57a decline in our stock price
12. 58In the ordinary course of our business, we, or the third parties with whom we work, process proprietary, confidential, and sensitive data, including personal data (such as health-related data), intellectual property, and trade secrets
13. 59heightened risk of these attacks, including retaliatory cyber-attacks, that could materially disrupt our systems and operations, supply chain, and ability to produce, sell and distribute our goods and services
14. 60Our contracts may not contain limitations of liability, and even where they do, there can be no assurance that limitations of liability in our contracts are sufficient to protect us from liabilities, damages, or claims related to our data privacy and security obligations

Risks Related to Our Common Stock

1. 61Our stock price historically has been, and is likely to remain, highly volatile
2. 62economic and political factors, including but not limited to economic and financial crises, wars, terrorism, and political unrest
3. 63If we or our stockholders sell substantial amounts of our common stock, the market price of our common stock may decline
4. 64If our officers, directors, and largest stockholders choose to act together, they may be able to significantly influence our management and operations, acting in their best interests and not necessarily those of our other stockholders
5. 65Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us more complicated and may make the removal and replacement of our directors and management more difficult
6. 66provide for a board of directors with staggered terms
7. 67We do not intend to pay dividends on our common stock in the foreseeable future; as such, you must rely on stock appreciation for any return on your investment